glp 1 care credit GLP-1 Weight Loss- Compounded Semaglutide – Lolachi Institute Weight Loss Surgery, Medication and

An additional 329 articles were identified through Google Scholar searches

Other significant safety considerations include a history of pancreatitis, acute kidney injury risk, diabetic retinopathy complications in patients with type 2 diabetes, gallbladder disease, hypoglycemia risk in patients using other diabetes medications, and mental health monitoring for mood changes or suicidal ideation

Semaglutide and tirzepatide dominate the current market and have made GLP-1 producers Novo Nordisk and Eli Lilly 2 of the top 3 pharma companies by market cap 2 Largest pharma companies by market cap

Some providers report modest additional benefit beyond monotherapy, but many patients achieve excellent results on optimized single-agent dosing first

It shouldn't be more than that